A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma Patients

• Published in: Blood 2004-11, Vol.104 (11), p.3462-3462
• Main Authors: Mateos, M.V., Blade, Joan, Mediavilla, J. Diaz, Lahuerta, J.J., Terol, M.J., Hernández, J., Moro, M.J., Bargay, J., Ribera, J.M., de la Rubia, J., Sureda, A., Carrera, D., de Arriba, F., Palomera, L., Hernández, M., Laraña, J. García, Alegre, A., Prosper, F., Rivas, P., Esseltine, D.L., Schenkein, D., Miguel, J.F. San
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V104.11.3462.3462

For more than 25 years, melphalan and prednisone has remained as the gold standard treatment for elderly multiple myeloma (MM) patients. Bortezomib has shown significant activity with manageable toxicity in refractory/relapse MM patients. Moreover, in vitro synergy has been reported when bortezomib is combined with cytotoxic agents such as melphalan. Aim: To define the appropriate dose of bortezomib in combination with MP and to analyse the efficacy of V-MP in untreated MM patients ≥ 65 years old. Methods: This is a dose escalation study with two sequential dose levels (Ph 1) and expansion of the cohort at the MTD by 60 patients to further refine estimates of efficacy (Ph 2). In the first cohort, bortezomib (1mg/m2) was administered as a iv bolus to 6 consecutive patients on days 1,4,8,11,22,25,29 and 32 followed by a 10 day rest period in combination with oral melphalan, 9 mg/m2, and prednisone, 60mg/m2, once daily on days 1 to 4. In the 2nd cohort, bortezomib was administered at 1.3mg/m2. MTD was defined as that dose level below which 2/6 patients had a DLT. Patients: 12 patients have been enrolled to date - 6 in cohort 1 and 6 in cohort 2. Results: Toxicity has been manageable. The first cohort at 1 mg/m2 has completed at least two 6-week treatment cycles. There was no DLT in the first cycle. The 2nd cohort has enrolled 6-patients at a dose of 1.3 mg/m2 but none has completed the first cycle yet. In the first cohort, there was one patient with grade 3 neutropenia (ANC = 0,668) observed at Cycle 1 Day 25. During the second cycle, there were no patients with grade 4 therapy-related toxicity and only one grade 3 adverse event (neutropenia) was observed. The most common grade1 or 2 toxicities were nausea, vomiting, rash, constipation, diarrhea, fever, herpes zoster infection, anorexia, neutropenia, anemia and thrombocytopenia. Ocular neuropathic pain (grade 2) developed de novo in 1 patient during the first cycle; one dose of bortezomib was held and the adverse event resolved with analgesic treatment in 4 days. Treatment was continued at a dose of 0,5 mg/m2 at D11 and D22. After this date, bortezomib at 1.0 mg/m2 was restarted. The second cohort is in the first 6-week cycle at present, so observations are limited. One serious adverse event (pulmonary embolism and probably septic shock with death) was observed in this cohort in a patient at day +11. He had normal WBC. Two grade 3 adverse events (leucopenia and neutropenia) were observed in one patient. Other